Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA). Key products include ORTHOVISC (osteoarthritis treatment, marketed internationally but investigational in the U.S.), HYVISC (equine osteoarthritis), and ophthalmic viscoelastic products (AMVISC, CoEase, etc.) manufactured for third parties.
Key Financial Metrics (Year Ended Dec 31, 2002)
| Metric | 2002 | 2001 |
|---|---|---|
| Total Revenue | $13.19 million | $11.31 million |
| Product Revenue | $13.13 million | $11.30 million |
| Gross Profit | $5.08 million | $3.08 million |
| Gross Margin | 39% | 27% |
| Net Loss | $(3.04) million | $(6.76) million |
| Loss Per Share (Diluted) | $(0.31) | $(0.68) |
| Cash & Cash Equivalents | $11.00 million | $9.06 million |
| Marketable Securities | $2.50 million | $3.99 million |
| Total Assets | $20.09 million | $22.92 million |
| Working Capital | $14.92 million | $16.76 million |
| Accumulated Deficit | $(14.40) million | $(11.36) million |
Debt & Liquidity: The company reported no long-term debt. Total current liabilities were $3.02 million. Cash provided by operating activities was $0.33 million, a significant improvement from cash used in operating activities of $4.31 million in 2001.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 16% to $13.19 million, driven by a 30% increase in ophthalmic product sales and a 71% increase in HYVISC sales. This was partially offset by a 27% decline in ORTHOVISC sales due to market share erosion in Turkey and pricing pressures in Europe.
- Profitability Improvement: The net loss narrowed significantly from $6.76 million in 2001 to $3.04 million in 2002. Gross margin expanded from 27% to 39% due to improved manufacturing efficiency, reduced work-in-process inventory, and the absence of a $0.95 million litigation settlement cost incurred in 2001.
- Expense Reduction: Operating expenses decreased 20% to $8.35 million. Selling, general, and administrative (SG&A) expenses dropped 16% due to lower professional fees and the absence of 2001 management separation costs. R&D expenses decreased 8% due to lower personnel costs, partially offset by Phase III clinical trial costs for ORTHOVISC.
- Restatement: The company restated results for the three and nine months ended September 30, 2002, reducing revenue by $326,480 and increasing net loss by $169,770. This was due to the improper recognition of revenue for HYVISC units manufactured in a clean room lacking FDA regulatory approval.
Guidance, Outlook, and Risks
- Regulatory Outlook: Anika expects to compile data from its third Phase III clinical trial of ORTHOVISC and submit a Pre-Market Approval (PMA) application to the FDA in the first half of 2003. There is no assurance that the data will support approval.
- Financial Outlook: Management expects 2003 R&D expenses to decrease as the ORTHOVISC trial concludes, while SG&A expenses may remain flat due to increased marketing efforts for ORTHOVISC offset by lower professional fees. The company believes its cash and investments ($13.5 million total) are sufficient to fund operations through the end of 2003.
- Key Risks:
- Customer Concentration: Bausch & Lomb accounted for 59% of product revenue in 2002. The supply agreement is subject to early termination and price adjustments based on volume.
- Regulatory Approval: Failure to obtain FDA approval for ORTHOVISC or INCERT-S would materially adversely affect the business.
- Manufacturing Compliance: The restatement highlighted risks regarding manufacturing in facilities without specific regulatory approvals. The company is seeking FDA approval for a new clean room to resume full HYVISC production.
- SEC Investigation: The company settled an SEC investigation regarding historical revenue recognition for ORTHOVISC sales to Zimmer, Inc. No monetary sanctions were imposed, but the settlement required compliance orders.
Investor Verification Checklist
- Restatement Impact: Verify the status of the $292,734 HYVISC inventory produced in the unapproved clean room and the timeline for FDA approval of the facility.
- ORTHOVISC Clinical Data: Monitor the submission and FDA review of the Phase III clinical trial data expected in H1 2003.
- Bausch & Lomb Agreement: Review the terms of the exclusive supply agreement, specifically volume-based pricing adjustments and termination clauses.
- Cash Burn Rate: Assess whether the $13.5 million in liquid assets is sufficient to sustain operations if ORTHOVISC approval is delayed beyond 2003.
- Customer Diversification: Evaluate progress in securing new distributors for ORTHOVISC to reduce reliance on Bausch & Lomb and mitigate international market volatility (e.g., Turkey).